Last reviewed · How we verify
NCT07269652
HappyOrNot® Smileys and the Visual Analogue Scale (VAS) in the Assessment of Urinary Symptoms
NA trial testing Visual analogue scale and HappyorNot smileys in Prostate Hyperplasia in 100 participants. Completed in 1 May 2025.
1 May 2025
Quick facts
| Lead sponsor | Seinajoki Central Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 1 August 2022 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across Finland |
Drugs / interventions tested
- Visual analogue scale and HappyorNot smileys
Conditions studied
- Prostate Hyperplasia — all drugs for Prostate Hyperplasia →
Sponsor
Seinajoki Central Hospital
Who can join
Eligibility, male only, with Prostate Hyperplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
INTRODUCTION A simple and repeatable test would be valuable for assessing the severity and impact of urinary symptoms. Visual Analogue Scale (VAS) is a 10 cm line where a participant put a mark in place that describes best his satisfaction with woiding. VAS has been shown to correlate with flowmetry and International Prostate Symptom Score (IPSS). VAS is still a number and may not reflect participants satisfaction. HappyorNot smileys (HoN) (emoji faces) are used to measure customer satisfaction by pressing one of four emoji smilyes. Two of these are happy and two and unhappy. OBJECTIVE: \- To study the use of VAS and HoN in assessing urinary symptoms in men. MATERIALS AND METHODS: * 100 men referred to urology outpatient clinic in Tampere University Hospital or Seinäjoki Central Hospital due to urinary symptoms caused by benign Prostate Hyperplasia (BPH) * Participants are asked to fill VAS and HoN and results are correlated with traditional symptom questionnaires and peak urinary flow and post-void residual volume.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07269652
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Hyperplasia
Currently open trials in the same condition.
- NCT06865430 — Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker · NA · recruiting
- NCT06834152 — Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE) · recruiting
- NCT06224218 — Prostate Single Port & Laser Enucleation Comparison Trial · NA · recruiting
- NCT05443451 — BETTY: BEnign Prostatic Hyperplasia Transperineal Targeted Microwave therapY · NA · recruiting
- NCT06116851 — Prostate Metabolism, Cancer Risk and Gut Microbiota · recruiting
Other Seinajoki Central Hospital trials
Trials by the same sponsor.
- NCT07324590 — Thermal Imaging in the Diagnosis of Acute Testicular Pain · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07269652 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seinajoki Central Hospital
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07269652.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing